Newsroom | 222622 results

MONTPELLIER, France & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced the selection of SENS-601 which addresses GJB2-related hearing loss as its lead program. A Clinical trial application has been filed in Canada and France to evaluate the safety, tolerability and efficacy of intra-cochlear...

TOKYO--(BUSINESS WIRE)--This year marks the 35th awarding of the Blue Planet Prize, the international environmental award sponsored by the Asahi Glass Foundation, chaired by Takuya Shimamura. Every year, the Foundation selects two laureates, individuals, or organizations who have made significant contributions towards the resolution of global environmental problems. The Board of Directors has selected the following 2026 Blue Planet Prize laureates. 1. Dr. Linda S. Birnbaum (USA) born December 2...

香港--(BUSINESS WIRE)--（ビジネスワイヤ） -- オアシス・マネジメント・カンパニー・リミテッド（以下「オアシス」または「当社」）は、株式会社エス・エム・エス（2175 JP）（以下「SMS」または「同社」）の株式を18.3%保有するファンドの運用会社として、より「強い」SMSキャンペーンを5月28日に発表しました。 オアシスは、来る株主総会にてSMSの株主の皆様に対し、以下の2点を求めています。 代表取締役社長である高畑 正樹氏の再任案への反対 社外取締役である高木 暢子氏の再任案への反対 オアシスは、株主、従業員、取引先、その他ステークホルダーの皆様に我々の主張を伝えるため、キャンペーンサイト「ABetterSMS.com」を開設し、リーダーシップ刷新の必要性を説明する詳細なプレゼンテーション資料を公開しています。 本プレゼン資料はこちらからご覧いただけます。 SMSは6月5日付で、オアシスが発表したキャンペーンに対する見解を公表しました。しかし、その内容には、これまでの経営責任や企業価値の毀損に正面から向き合う姿勢ではなく、自社の取り組みを正当化し、現体制の維...

HONG KONG--(BUSINESS WIRE)--Oasis Management Company Ltd. (“Oasis”), the investment manager to private funds that own approximately 18.3% of the shares in SMS Co., Ltd. (2175 JP) (“SMS” or the “Company”), launched the “A Better SMS” campaign on May 28. For the upcoming SMS AGM, Oasis is calling on fellow shareholders to: Vote AGAINST the reappointment of President Masaki Takahata as a director; and Vote AGAINST the reappointment of Nobuko Takagi as a director. To make its case directly to fello...

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced the appointment of Darlene Deptula-Hicks to Aldeyra’s board of directors (the Board). “Ms. Deptula-Hicks brings decades of experience working with both publicly traded and venture-backed biotechnology companies,” stated Richard H. Douglas, Ph.D., Chairman of the Board...

AMSTERDAM--(BUSINESS WIRE)--Avanzanite Bioscience B.V., een snel groeiend Europees bedrijf dat gespecialiseerde farmaceutica produceert met bijzondere aandacht voor zeldzame ziekten, kondigde vandaag de uitbreiding van de activiteiten naar Spanje aan en de benoeming van María Baquerizo López-Quectuy tot Spain Country Manager. Dit volgt na een Serie A-investering van €32 miljoen door MVM Partners aangekondigd in november 2025 en de recente toegang in Frankrijk. Avanzanite blijft zijn geïntegreer...

AMSTERDAM--(BUSINESS WIRE)--Avanzanite Bioscience B.V. ist ein schnell wachsendes europäisches Pharmazieunternehmen für die kommerzielle Phase, das auf seltene Krankheiten spezialisiert ist. Es gab heute bekannt, dass es nach Spanien expandiert und María Baquerizo López-Quectuy als Managerin für dieses Land ernennt. Dieser Schritt folgt auf ein Series-A-Investment in Höhe von €32 Millionen durch MVM Partners , das im November 2025 bekannt wurde und dem Eintritt in den französischen Markt. Avanz...

SALEM, N.H.--(BUSINESS WIRE)--Analogic Corporation, a global leader in advanced imaging and detection technology, today opened its new global engineering, manufacturing, and administrative headquarters at 9 Northeastern Boulevard, Salem, NH. New Hampshire Governor Kelly Ayotte joined Analogic CEO Tom Ripp, Board Member George Aitken-Davies, and state and local leaders for the official ribbon-cutting. The new campus consolidates Analogic's global operations under one roof and will bring approxim...

AMSTERDAM--(BUSINESS WIRE)--Avanzanite Bioscience B.V., società farmaceutica di fase commerciale in rapida crescita specializzata nelle patologie rare, oggi annuncia l'espansione delle proprie attività in Spagna e la nomina di María Baquerizo López-Quectuy a Country Manager per il paese iberico, a seguito di un investimento di serie A del valore di 32 milioni di euro da parte di MVM Partners, annunciato nel mese di novembre 2025, e del recente debutto dell'azienda sul mercato francese. Avanzani...

AMSTERDAM--(BUSINESS WIRE)--Avanzanite Bioscience B.V., une société pharmaceutique européenne spécialisée dans les maladies rares, en phase commerciale et en pleine croissance, a annoncé aujourd’hui son implantation en Espagne et la nomination de María Baquerizo López-Quectuy au poste de directrice nationale pour l’Espagne. Cette annonce fait suite à un investissement de série A de 32 millions d’euros réalisé par MVM Partners, annoncé en novembre 2025, et à la récente implantation de la société...